This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (18)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Terry Y. Shibuya, MD; Wei-Zen Wei, PhD; Michelle Zormeier, MD; John Ensley, MD; Wael Sakr, MD; Robert H. Mathog, MD; Robert J. Meleca, MD; George H. Yoo, MD; Carl H. June, MD; Bruce L. Levine, PhD; Lawrence G. Lum, MD

Arch Otolaryngol Head Neck Surg. 2000;126:473-479.

Objectives  To test whether T-cell CD3 responses are altered in patients with advanced-stage head and neck squamous cell carcinoma (HNSCC) and whether anti-CD3/anti-CD28 (CD3/CD28) bead stimulation could reverse CD3 unresponsiveness.

Design  Anti-CD3 (CD3) monoclonal antibody immobilized on tissue culture plastic was used to stimulate lymph node mononuclear cells (LNMCs) and peripheral blood mononuclear cells (PBMCs) from patients with advanced-stage HNSCC. Proliferation, T-cell phenotype, and cytokines were measured during 8-day in vitro stimulation. Immune-enhancing properties of CD3/CD28 beads were also tested on LNMCs and PBMCs. Cytotoxicity of bead-activated T cells (ATCs) was measured against autologous and allogeneic HNSCC.

Results  Six patients were nonresponders to CD3 stimulation defined by tritium (³H) incorporation of less than 3500 cpm, whereas 11 patients were responders with ³H incorporation of 3500 cpm or more. Responders produced higher levels of interleukin (IL)–12 and interferon (IFN-) after CD3 stimulation than nonresponders. No phenotypic or clinical differences were identified between groups. Stimulation with CD3/CD28 beads enhanced IFN- and IL-2 produced by both groups. Bead ATCs were generated from PBMCs of patient 11 in the responder group and lysed (± SD) 100% ± 1% of autologous tumor and 49% ± 1% of allogeneic tumor. Bead ATCs from LNMCs of this patient lysed 58% ± 1% of autologous tumor and 63% ± 1% of allogeneic tumor.

Conclusions  A subpopulation of patients with HNSCC who are nonresponders to CD3 stimulation has been identified, showing reduced proliferation and IL-12 and IFN- secretion. Nonresponders stimulated with CD3/CD28 beads reversed immune unresponsiveness and induced a type 1 cytokine response. Bead-generated ATCs from patient 11 in the responder group lysed autologous and allogeneic HNSCC in vitro, suggesting a possible effective immunotherapeutic modality in the treatment of HNSCC.

From the Departments of Otolaryngology–Head and Neck Surgery (Drs Shibuya, Zormeier, Mathog, Meleca, and Yoo), Immunology-Microbiology (Dr Wei), Medicine (Dr Ensley), and Pathology (Dr Sakr), Wayne State University School of Medicine, and the Karmanos Cancer Institute (Drs Wei, Ensley, and Sakr), Detroit, Mich; the Departments of Molecular and Cellular Engineering and Medicine, University of Pennsylvania Cancer Center, Philadelphia (Drs June and Levine); and the Immunotherapy Research and Treatment Institute, St Luke's Medical Center, Milwaukee, Wis (Dr Lum).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

CD3/CD28-costimulated T1 and T2 subsets: differential in vivo allosensitization generates distinct GVT and GVHD effects
Jung et al.
Blood 2003;102:3439-3446.
ABSTRACT | FULL TEXT